117 KENDRICK STREET, NEEDHAM, MA
Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
News, Material Contracts
Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Announces $15 Million Registered Direct Offering of Common Stock
Appoints Charles Schoch as Chief Financial Officer
Shareholder votes
Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
Q2
Q1
FY 2024
FY 2023 amended
FY 2023
Q3
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence